Bracco Diagnostics Inc. Introduces CitraClear™, a Refreshing Pre-Procedure Hydration Solution, to the Healthcare Community

Patients Now Have Another Option to Prepare for Medical Procedures

MONROE TOWNSHIP, N.J., Sept. 23, 2024 /PRNewswire/ -- Bracco Diagnostics Inc. (BDI), the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, proudly unveils CitraClear^™, a pre-procedure hydration beverage designed with patients in mind.  As an alternative to traditional options such as milk, water, or juice, CitraClear^™ offers patients a gutsy-filling experience.

Developed with patient comfort and compliance in mind, CitraClear^™ addresses the need for a hydration option that eliminates the disadvantages of soda, including excess sugar and carbonation. Doctors and healthcare providers now have another alternative to offer patients as they prepare for medical procedures.

CitraClear^™ offers a refreshing distinct flavor profile that provides patients with a pleasant hydration experience. It also caters to a wide range of patients' diverse dietary needs as CitraClear^™ is gluten-free. Being sugar and carbonation-free, unlike soda, CitraClear^™ is an ideal choice for patients seeking healthier beverage options.

"CitraClear^™ represents an advancement in patient experience," says Cosimo De Pinto, Senior Vice President Sales and Marketing at BDI. "We recognized the need for a beverage that hydrates patients effectively and supports dietary preferences and restrictions. CitraClear™ meets these criteria and offers a compelling solution."

As healthcare professionals increasingly prioritize patient comfort and satisfaction, CitraClear^™ emerges as a versatile solution that enhances the pre-procedure experience. Its unique formulation and enticing flavor profile set a new standard for patient hydration in medical settings.

CitraClear^™ is now available for procurement through authorized distributors. For more information about CitraClear^™ and its benefits, please visit http://imaging.bracco.com/us-en.

CITRACLEAR is manufactured by E-Z-EM Canada Inc. for Bracco Diagnostics Inc.  

CITRACLEAR is a trademark of E-Z-EM, Inc.  

For additional information about Bracco's products, and for full prescribing information, please visit http://imaging.bracco.com/us-en. 

About Bracco Imaging

Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has approximately 3,600 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. R&D activities are located in four centers based in Italy, Switzerland, the United Kingdom, and the United States. Bracco Group global revenues were 1.4 billion Euros in 2020. To learn more about Bracco Imaging,

Bracco Diagnostics Inc. Media Relations (USA)
Kimberly Gerweck
Senior Manager, Marketing Communications
[email protected]
D: +1 609-524-2777

SOURCE Bracco Group